

PredicineWES+™

Liquid Biopsy Whole Exome Sequencing

Genome-wide Molecular Insights


Genomic profiling of cell-free DNA (liquid biopsy) using whole exome sequencing (WES) provides insights into genome-wide variation and an unrivaled resolution of structural variations, rearrangements, and exon duplicates.

Liquid Biopsy Sequencing

Predicine's comprehensive liquid biopsy sequencing solution offers rapid turnaround time for critical clinical applications. From a single sample, we provide low-pass whole genome sequencing (LP-WGS) data combined with broader coverage using WES and/or in-depth profiling using PredicineCARE or PredicineATLAS focused pan cancer panels, based on tumor fraction from the sample.

LP-WGS information is perfect for screening purpose and allows for informed decision making as to the additional breadth and depth of coverage provided by whole exome or focused pan-cancer panel sequencing.

Workflow Flexibility



Input Requirement

5-10ml blood, 4-6ml plasma, or 5-30ng cfDNA
40ml urine

Deliverables

- Tumor fraction & ploidy analysis
- SNV, CNV, Indel and rearrangement
- TMB & MSI

Additional Information

- Designed for biopharma clinical trials
- Samples with tumor fraction (TF) >5% will proceed into the exome workflow, samples <5% are more suited for a focused panel such as PredicineCARE (152 genes) or PredicineATLAS (600 genes)